日常の臨床診療における乾癬性関節炎の参加者におけるグセルクマブおよびインターロイキン-17(IL-17)阻害剤療法の研究 (PsABIOnd)
日常の臨床診療における乾癬性関節炎患者におけるグセルクマブ (Tremfya) および IL-17 阻害剤療法の評価。前向き観察コホート研究
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Psoriatic arthritis (PsA) is a seronegative inflammatory spondylarthritis associated with psoriasis (PsO), which can cause pain and swelling in the joints, sausage-shaped swelling of the fingers and toes (dactylitis), inflammation of the muscle- or tendon insertions at adjacent bone (enthesitis), as well as raised red patches or various other expressions of psoriasis on the skin. Guselkumab (TREMFYA) is a fully human immunoglobulin G1 lambda (IgG1) monoclonal antibody (mAb) that binds to the p19 subunit of human interleukin (IL) 23 with high specificity and affinity, blocking IL-23 binding. Binding of guselkumab to the IL-23p19 subunit blocks the subsequent binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling and subsequent activation and cytokine production. Participants with confirmed diagnosis of PsA who are starting guselkumab or any marketed interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of PsA biologic therapy per standard clinical practice will be enrolled in the main study. The aim of main study is to document the use of guselkumab and approved IL-17i therapies in routine clinical practice in patients with PsA who are starting guselkumab or an IL-17i as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy. The overall duration of the main study, including recruitment and follow-up, is expected to be about 6 years. Participants who are starting guselkumab or an IL-17i treatment per routine clinical practice in the main study, and who meet the selection criteria for both the main study and substudy, will be consecutively offered entry into the substudy (a select number) at the time of enrollment into the main study. The substudy aims to collect additional data, continuously or with increased frequency, on the impact of guselkumab or IL-17i on patient mood, physical activity, sleep disturbance, disease symptoms, and health-related quality-of-life (HRQoL). Total duration of the substudy will be approximately 26-30 weeks consisting of a pre-treatment period of up to 14 days before the first dose of guselkumab or IL-17i in the main study and a 24-week (plus [+] up to 4 weeks follow-up) observation period.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
-
Buenos Aires、アルゼンチン、C1199ABB
- Hospital Italiano de Buenos Aires
-
Buenos Aires、アルゼンチン、C1221ADC
- Hospital J. M. Ramos Mejía
-
Buenos Aires、アルゼンチン、C1015ABO
- OMI
-
Córdoba、アルゼンチン、5000
- Hospital Cordoba
-
San Fernando、アルゼンチン、B1646
- MR Medicina Reumatologica
-
-
-
-
-
Aberdeen、イギリス、AB25 2ZB
- NHS Grampian - Aberdeen Royal Infirmary (ARI)
-
Abergavenny、イギリス、NP7 7EG
- Nevill Hall Hospital
-
Airdrie、イギリス、ML6 0JS
- University Hospital Monklands
-
Barnet、イギリス、EN5 3DJ
- Royal Free London NHS Foundation Trust Barnet Hospital
-
Bath、イギリス、BA1 3NG
- Wolfson Centre Royal United Hospitals
-
Glasgow、イギリス、650029
- Glasgow Royal Infirmary
-
Hull、イギリス、HU3 2JZ
- Hull Royal Infirmary
-
Leeds、イギリス、LS7 4SA
- Leeds Teaching Hospitals NHS Trust Chapel Allerton Hospital
-
Manchester、イギリス、M13 9WL
- Central Manchester University Hospitals NHS Foundation Trust
-
Newcastle upon Tyne、イギリス、NE7 7DN
- The Newcastle upon Tyne Hospitals NHS Trust - Freeman Hospit
-
Portsmouth、イギリス、PO6 3LY
- Queen Alexandra Hospital
-
Salford、イギリス、M6 8HD
- Shirley Caldwell
-
Southampton、イギリス、SO16 6YD
- Southampton General Hospital
-
Staffordshire、イギリス、ST6 7AG
- Haywood Hospital
-
Stamford、イギリス、PE9 1UA
- Stamford and Rutland hospital
-
Wishaw、イギリス、ML2 0DP
- Wishaw General
-
-
-
-
-
Bari、イタリア、70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
Campobasso、イタリア、86100
- Ospedale Regionale Cardarelli-Università degli Studi del Mol
-
Catanzaro、イタリア、88100
- Universita della Magna grecia
-
Florence、イタリア、50141
- AOU Careggi
-
Naples、イタリア、80131
- Azienda Ospedaliera Universitaria Federico II
-
Naples、イタリア、80131
- Seconda Univesità degli Studi di Napoli, AOU
-
Palermo、イタリア、90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pisa、イタリア、56126
- Azienda Ospedaliero Universitaria Pisana
-
Potenza、イタリア、85100
- Ospedale San Carlo Di Potenza - Azienda Ospedaliera Regionale
-
Rome、イタリア、20123
- Universita Cattolica del Sacro Cuore
-
Rozzano、イタリア、20156
- Istituto Clinico Humanitas
-
Torino、イタリア、10126
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
-
Udine、イタリア、33100
- Azienda Ospedaliero Universitaria S.Maria Della Misericordia
-
Verona、イタリア、37067
- Azienda Ospedaliera Universitaria Integrata Verona
-
-
-
-
-
Amsterdam、オランダ、1105 AZ
- Academisch Medisch Centrum Universiteit van Amsterdam
-
Enschede、オランダ、7500 KA
- Medisch Spectrum Twente
-
Groningen、オランダ、9700 RB
- Universitair Medisch Centrum Groningen
-
Helmond、オランダ、5707 HA
- Elkerliek Ziekenhuis
-
-
-
-
-
Adelaide、オーストラリア、5011
- The Queen Elizabeth Hospital
-
Footscray、オーストラリア
- Footscray Hospital, Western Health
-
St Leonards、オーストラリア、2065
- Royal North Shore Hospital
-
-
-
-
-
Graz、オーストリア、8036
- LKH-Univ. Klinikum Graz
-
Linz、オーストリア、4021
- Kepler Universitatsklinikum GmbH
-
Vienna、オーストリア、1090
- Medizinische Universitaet Wien
-
Vienna、オーストリア、A-1100
- Evang. Krankenhaus Gemein. Betriebgesm. Mbh
-
-
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 1J9
- Artus Health Centre
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3A 1M3
- Manitoba Clinic
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1C 5B8
- St. Claire's Mercy Hospital - Rheumatology Research
-
-
Nova Scotia
-
Coxheath、Nova Scotia、カナダ、B1L 1B3
- Dr. Juris Lazovskis Incorporated
-
-
Ontario
-
Dundas、Ontario、カナダ、L9H 1B7
- Private Practice - Dr. Pauline Boulos
-
Markham、Ontario、カナダ、L3R 2C7
- Markham Rheumatology Hub
-
Mississauga、Ontario、カナダ、L5A 3V8
- Brandusa Florica Medicine Professional Corporation
-
Orillia、Ontario、カナダ、L3V 1T5
- The Waterside Clinic
-
Ottawa、Ontario、カナダ、K1H 7W9
- The Ottawa Hospital Research Institute
-
Windsor、Ontario、カナダ、N8X 1T3
- Dr Sabeen Anwar Medicine Professional Corporation
-
-
Quebec
-
Montreal、Quebec、カナダ、H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
Québec、Quebec、カナダ、G1V 4K5
- G R M O Groupe de recherche en maladies osseuses Inc
-
Rimouski、Quebec、カナダ、G5L 5T1
- Centre de sante et services sociaux (CSSS) de Rimouski-Neigette - Hopital regional - Rimouski
-
Trois-Rivières、Quebec、カナダ、G9A 3X2
- Centre de Recherche Musculo Squelettique
-
-
Saskatchewan
-
Saskatoon、Saskatchewan、カナダ、S7K 0H6
- Community Rheumatology Care
-
Saskatoon、Saskatchewan、カナダ、S7K 0H6
- Rheumatology Associates of Saskatoon
-
-
-
-
-
Athens、ギリシャ、10676
- Evangelismos General Hospital of Athens
-
Athens、ギリシャ、11527
- Laiko General Hospital of Athens
-
Athens、ギリシャ、11521
- Athens Navy Hospital
-
Athens、ギリシャ、11527
- General Hospital 'Gennimatas'
-
Athens、ギリシャ、11527
- Hippokration General Hospital of Athens, B' Internal Medicine Clinic,
-
Ioannina、ギリシャ、45560
- University Hospital of Ioannina
-
Pátrai、ギリシャ、263 32
- 'Agios Andreas' General Hospital of Patras
-
Pátrai、ギリシャ、26500
- University General Hospital of Rio Patras
-
Thessaloniki、ギリシャ、546 42
- Ippokrateio Hospital
-
-
-
-
-
Bogotá、コロンビア
- BIOMAB
-
Bucaramanga、コロンビア
- Servimed S A S
-
Medellín、コロンビア、50012
- Clinisalud del Sur
-
Medellín、コロンビア、50025
- Clinica Vascular las Americas
-
Montería、コロンビア、230002
- Funcentra
-
-
-
-
-
Fribourg、スイス、1708
- HFR Fribourg - Hôpital Cantonal
-
-
-
-
-
Gothenburg、スウェーデン、41345
- Sahlgrenska Universitetssjukhuset
-
Malmö、スウェーデン、20502
- Universitetssjukhuset i Lund
-
Stockholm、スウェーデン、113 65
- Akademiskt Specialistcentrum centrum för reumatologi
-
Uppsala、スウェーデン、75185
- Akademiska Sjukhuset
-
Örebro、スウェーデン、70185
- Universitetssjukhuset Orebro
-
-
-
-
-
A Coruña、スペイン、15006
- Hosp Univ A Coruna
-
Algeciras / Cadiz、スペイン、11207
- Hosp. Punta de Europa
-
Barcelona、スペイン、08036
- Hosp Clinic de Barcelona
-
Barcelona、スペイン、8035
- Hosp Univ Vall D Hebron
-
Bilbao、スペイン、48013
- Hosp. Univ. de Basurto
-
Córdoba、スペイン、14004
- Hosp Reina Sofia
-
Granada、スペイン、18016
- Complejo hospitalario de Granada
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28905
- Hosp. Univ. de Getafe
-
Oviedo、スペイン、33011
- Hosp. Univ. Central de Asturias
-
Santiago de Compostela、スペイン、15706
- Hosp. Clinico Univ. de Santiago
-
Seville、スペイン、41013
- Hosp. Virgen Del Rocio
-
-
-
-
-
Amberg、ドイツ、92224
- Praxis für Rheumatologie
-
Bayreuth、ドイツ、95444
- Rheuma-Praxis Bayreuth
-
Berlin、ドイツ、12161
- Rheumatologische Schwerpunktpraxis
-
Berlin、ドイツ、13055
- Rheumatologische Schwerpunktpraxis 1
-
Cologne、ドイツ、51149
- Krankenhaus Porz am Rhein
-
Düsseldorf、ドイツ、40225
- Universitatsklinikum Dusseldorf
-
Erfurt、ドイツ、99096
- Service Rheuma Erfurt
-
Frankfurt、ドイツ、60590
- Universitatsklinikum Frankfurt
-
Halle、ドイツ、6128
- Rheumapraxis Dr. Liebhaber
-
Hamburg、ドイツ、22767
- Rheumatologie im Struenseehaus
-
Hamburg、ドイツ、22415
- Praxis fur Klinische Studien und Praxis fur Orthopadie
-
Herne、ドイツ、44649
- Rheumazentrum Ruhrgebiet
-
Leipzig、ドイツ、04109
- Rheumatologische Praxis 1
-
Magdeburg、ドイツ、39104
- Rheumatologische Praxis
-
München、ドイツ、81541
- Praxiszentrum St. Bonifatius
-
Neubrandenburg、ドイツ、17033
- Praxis Thilo Klopsch
-
Püttlingen、ドイツ、66346
- Knappschaftsklinikum Saar GmbH Klinik für Rheumatologie
-
Ratingen、ドイツ、40878
- Rheumazentrum Ratingen
-
Templin、ドイツ、17268
- Rheumatologisch-immunologische Arztpraxis
-
Vogelsang-Gommern、ドイツ、39245
- Immunologisches Zentrum Vogelsang-Gommern GmbH
-
-
-
-
-
Bobigny、フランス、93000
- Hôpital Avicenne
-
Cholet、フランス、49300
- Centre Hospitalier de Cholet
-
Clermont-Ferrand、フランス、63003
- Hôpital Gabriel Montpied
-
Créteil、フランス、94000
- Centre Hospitalier Universitaire(CHU) - Hopital Henri Mondor
-
Lille、フランス、59037
- CHRU HOPITAL ROGER SALENGRO Consultation Appareil locomoteur
-
Lyon、フランス、69008
- Centre Orthopedique Santy
-
Lyon、フランス、69300
- Clinique de l'Infirmerie Protestante de Lyon
-
Nice、フランス、6006
- Hôpital Saint Roch
-
Orléans、フランス、45032
- CHR Orléans - Nouvel Hôpital Orléans La Source
-
Paris、フランス、75018
- Hôpital Bichat
-
Paris、フランス、75010
- Hôpital Lariboisière - Centre Viggo Petersen
-
Paris、フランス、75012
- Hopital Saint-Antoine
-
Paris、フランス、75651
- Hopital Pitie Salpetriere
-
Strasbourg、フランス、67098
- CHRU Hôpital de Hautepierre
-
Toulouse、フランス、31059
- Hopital Purpan
-
Échirolles、フランス、38130
- CHU Grenoble
-
-
-
-
-
Bruges、ベルギー、8000
- AZ Sint-Jan
-
Brussels、ベルギー、1070
- Hopital Erasme
-
Genk、ベルギー、3600
- Reumaclinic Genk-Hasselt
-
Leuven、ベルギー、3000
- UZ Leuven
-
Liège、ベルギー、4000
- CHU de Liège - Domaine Universitaire du Sart Tilman
-
-
-
-
-
Mérida、メキシコ、97070
- Medical Care & Research SA de CV
-
México、メキシコ、07760
- Consultorio de Reumatologia
-
Zapopan、メキシコ、45116
- Hospital Puerta de Hierro
-
-
-
-
-
Kemerovo、ロシア、G4 0SF
- SBEU HPE Kemerovo State Medical Academy
-
Moscow、ロシア、121552
- Bakoulev Scientific Center For Cardiovascular Surgery Rams
-
Moscow、ロシア、190068
- FGBU Research Institute of Rheumatology named V.A.Nasonova
-
Tomsk、ロシア、634045
- City Hospital #3
-
-
-
-
-
Kaohsiung City、台湾、81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung City、台湾、83301
- Chang Gung Medical Foundation
-
Taichung、台湾
- Taichung Veterans General Hospital
-
-
-
-
-
Hyōgo、日本、6751392
- Kita-harima Medical Center
-
Meguro-ku、日本、153-8515
- Toho University Medical Center, Ohashi Hospital
-
Osaka、日本、550 0006
- Public Interest Incorporated Foundation Nipoon Life Saiseikai Nippon Life Hospital
-
Osaka、日本、545 8586
- Osaka Metropolitan University Hospital
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Tokyo、日本、181 8611
- Kyorin University Hospital
-
-
-
-
-
Cheonan-si、韓国、31151
- Soonchunhyang University Cheonan Hospital
-
Seongnam、韓国、13620
- Seoul National University Bundang Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、07061
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population consists of participants initially treated for Psoriatic Arthritis (PsA) with guselkumab or interleukin-17 inhibitor (IL-17i) per routine clinical practice in accordance with clinical guidelines.
説明
Inclusion Criteria:
Main study:
- Have a confirmed diagnosis of PsA as determined by a rheumatologist with reference to Classification criteria for Psoriatic Arthritis (CASPAR)
- Start guselkumab or any approved interleukin-17 inhibitor (IL-17i) as a first, second, third, or fourth line of biologic disease-modifying antirheumatic drugs (bDMARD) therapy for the indication of PsA as part of standard clinical practice (according to local label, local regulations, and/or reimbursement requirements) at the time of enrollment into the observational study or within a maximum of 2 months after the initial baseline visit or after repeated baseline data collection
- Sign a participation agreement/Informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
- Able to read, understand, and intend to comply with completion of all Electronic patient-reported outcome (ePRO) instruments
- The treatment decision must be taken by the participating rheumatologist prior to, and independently of the participant's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
Substudy:
- Must sign the substudy ICF allowing data collection in accordance with local requirements
- Is scheduled to receive guselkumab or IL-17i, per routine clinical practice, in the main study
- Currently using or is willing to use wearables and/or commercial applications to track their disease within the course of their normal daily activities
Exclusion Criteria:
Main study:
- Start guselkumab or an IL-17i therapy as fifth or further line of biologic treatment
- Have already taken a specific IL-17i or IL-23i treatment and are planning on re-taking that specific treatment again
- Unwilling or unable to participate in long-term data collection
- Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study (that is, signing of informed consent)
- Currently enrolled in any interventional study or any Janssen-sponsored observational clinical study (contemporary participation into observational studies or registries not sponsored by Janssen is acceptable)
Substudy:
- Have an insufficient command of language to interact effectively with the smartphone application, in the opinion of the investigator at each site
- Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (example, compromise the well-being) or that could prevent, limit, or confound assessment
- Unwilling or unable to comply with substudy assessments
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Cohort 1: Guselkumab
Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.
他の名前:
|
|
Cohort 2: Interleukin-17 inhibitor (IL-17i)
Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice in main study. Participants who meet the selection criteria for both the main study and substudy, will be consecutively offered to be enrolled into the substudy at the time of enrollment into the main study. |
Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The Start and Stop Date of Guselkumab, as Applicable, For Each Participant
時間枠:Up to 39 months
|
The start and stop date, (first and last administration date, respectively) of guselkumab, as applicable, for each participant will be collected to document treatment persistence. |
Up to 39 months
|
|
The Start and Stop Date of Interleukin-17 Inhibitor (IL-17i), as Applicable, For Each Participant
時間枠:Up to 39 months
|
The start and stop date (first and last administration date respectively) of IL-17i, as applicable, for each participant will be collected to document treatment persistence. |
Up to 39 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from Baseline in 66 and 68 Joint Counts for Swelling and Tenderness, Respectively
時間枠:Baseline up to 39 months
|
Change from baseline in 66 and 68 joint counts for swelling and tenderness, respectively will be reported. Joints assessed include the distal interphalangeal, proximal interphalangeal, and metacarpophalangeal joints of the hands; the wrist, elbow, shoulder, acromioclavicular, sternoclavicular, temporomandibular, hip (excluded for swelling), knee, ankle, and midtarsal joints; and the metatarsophalangeal and proximal interphalangeal joints of the feet. |
Baseline up to 39 months
|
|
Change from Baseline in Rheumatologist's Global Assessment of Disease Activity-Psoriatic Arthritis (PGA-PsA)
時間枠:Baseline up to 39 months
|
The PGA-PsA will be documented using a Visual Analogue Scale (VAS) that ranges from "no PsA activity" (0 Millimeter [mm]) to "extremely active PsA" (100 mm). |
Baseline up to 39 months
|
|
Change from Baseline in Assessment of Dactylitis
時間枠:Baseline up to 39 months
|
The presence of and total number of digits of the hands and feet (that is, 0 to 20) with dactylitis will be documented. |
Baseline up to 39 months
|
|
Change from Baseline in Assessment of Enthesitis using Leeds Enthesitis Index (LEI)
時間枠:Baseline up to 39 months
|
The presence and a score of enthesitis will be documented using the LEI to evaluate the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: the lateral epicondyles (left and right), medial femoral condyles (left and right), and Achilles tendon insertions (left and right). |
Baseline up to 39 months
|
|
Change from Baseline in Nail Involvement
時間枠:Baseline up to 39 months
|
Nail involvement will be documented by recording the total number of nails of the hands and feet (that is, 0 to 20) with psoriatic nail changes. |
Baseline up to 39 months
|
|
Change from Baseline in Body Surface Area (BSA) Psoriasis (PSO) Skin Involvement
時間枠:Baseline up to 39 months
|
The BSA score indicates the surface area of the participant's body effected by psoriasis. |
Baseline up to 39 months
|
|
Change from Baseline in C-reactive Protein (CRP)
時間枠:Baseline up to 39 months
|
Change from baseline in CRP will be reported. |
Baseline up to 39 months
|
|
Change from Baseline in Minimal Disease Activity (MDA)/ Very Low Disease Activity (VLDA)
時間枠:Baseline up to 39 months
|
Change from Baseline in MDA/VLDA will be reported. |
Baseline up to 39 months
|
|
Change from Baseline in Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA/DAPSA)
時間枠:Baseline up to 39 months
|
DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
Baseline up to 39 months
|
|
Response as a Measure of Clinical Improvement in cDAPSA/DAPSA
時間枠:Up to 39 months
|
Response is defined as a clinical improvement in cDAPSA/DAPSA. DAPSA assesses the joint domain of PsA and is derived from the sum of the following components: Participant's assessment of pain on VAS (in centimeters), Participant's Global Assessment of Disease Activity on VAS (in centimeters), 66 and 68 joint counts for swelling and tenderness, respectively. |
Up to 39 months
|
|
Start and Stop Dates of All Treatments and the Sequence of Treatment Lines
時間枠:Up to 39 months
|
Start and stop dates of all treatments and the sequence of treatment lines will be reported. |
Up to 39 months
|
|
Percentage of Participants with Adverse Events (AEs)
時間枠:Up to 39 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 39 months
|
|
BSA PSO Skin Involvement
時間枠:Up to 39 months
|
The BSA score indicates the surface area of the participant's body affected by psoriasis. |
Up to 39 months
|
|
Rheumatic Disease Comorbidity Index
時間枠:Up to 39 months
|
Number of comorbid medical conditions of the study participants for the Rheumatic Disease Comorbidity Index will be reported. |
Up to 39 months
|
|
Change from Baseline in Fibromyalgia Rapid Screening Tool (FiRST)
時間枠:Baseline up to 6 months
|
FiRST will be used to help determine whether participants have chronic widespread pain or fibromyalgia syndrome at entry into the study. The FiRST is a validated questionnaire consisting of a combination of 6 items that can detect chronic widespread pain. |
Baseline up to 6 months
|
|
Change from Baseline in European Quality of Life (EuroQoL) 5-Dimensions 5-Levels Questionnaire (EQ-5D-5L)
時間枠:Baseline up to 39 months
|
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems, where Level 1: no problem, Level 2: slight problems, Level 3: moderate problems, Level 4: severe problems and Level 5: extreme problems. |
Baseline up to 39 months
|
|
Change from Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
時間枠:Baseline up to 39 months
|
The functional status of the participants will be assessed by the HAQ-DI. This 20-question self-administered instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area. |
Baseline up to 39 months
|
|
Change from Baseline in Psoriatic Arthritis Impact of Disease-12 (PsAID-12)
時間枠:Baseline up to 39 months
|
PsAID-12 is a validated, self-administered questionnaire that assesses the impact of PsA on participants' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly). |
Baseline up to 39 months
|
|
Change from Baseline in Patient Global Disease Activity Visual Analog Scale (VAS) Scores
時間枠:Baseline up to 39 months
|
The Patient Global Disease Activity VAS is a self-administered assessment with scores ranging from "very well" (0 mm) to "very poor" (100 mm) that assesses disease activity over the past week. |
Baseline up to 39 months
|
|
Change from Baseline in Pain VAS Score
時間枠:Baseline up to 39 months
|
The pain VAS is a self-administered assessment of average pain during the past week. The scale ranges from "no pain" (0 mm) to "the worst possible pain" (100 mm). |
Baseline up to 39 months
|
|
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
時間枠:Baseline up to 39 months
|
BASDAI consists of a 1 through 10 scale (1 being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. |
Baseline up to 39 months
|
|
Change from Baseline in Ankylosing Spondylitis Disease Activity Score - C-reactive protein (ASDAS-CRP)
時間枠:Baseline up to 39 months
|
The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the CRP value. |
Baseline up to 39 months
|
|
Change from Baseline in Dermatology Life Quality Index (DLQI)
時間枠:Baseline up to 39 months
|
The DLQI is a dermatology-specific, validated, 10-question quality of life instrument used to measure the impact of skin disease on the quality of life of an affected person. Each question will address how much the participant's skin problem has affected their life and is scored as: 3 = very much, 2 = a lot, 1 = a little, 0 = not at all, or not relevant. |
Baseline up to 39 months
|
|
Change from Baseline in Patient Acceptable Symptom State (PASS)
時間枠:Baseline up to 39 months
|
The PASS measures the level of symptoms beyond which participants consider themselves well. The PASS addresses the concepts of low disease activity, partial remission in symptoms, and well-being. |
Baseline up to 39 months
|
|
Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI: PsA)
時間枠:Baseline up to 39 months
|
The WPAI: PsA is a validated, self-administered questionnaire that assesses work and activity impairment during the past 7 days. The WPAI: PsA produces 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work/reduced on-the-job effectiveness), work productivity loss (overall work impairment/absenteeism plus presenteeism), and activity impairment. The WPAI: PsA outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, that is, worse outcomes. |
Baseline up to 39 months
|
|
Change from Baseline in Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9)
時間枠:Baseline up to 39 months
|
TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and side effects of the medication. |
Baseline up to 39 months
|
|
Number of Participants Switching or Stopping Treatment
時間枠:Up to 39 months
|
Number of Participants switching or stopping treatment (including reasons for discontinuation) will be reported. |
Up to 39 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Janssen Pharmaceutica N.V., Belgium Clinical Trial、Janssen Pharmaceutica N.V., Belgium
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CR108938
- CNTO1959PSA4001 (その他の識別子:Janssen Research & Development, LLC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。